In short
Clinical trials investigating "XENON (133XE)" are studying how it can be used in imaging to measure lung function before and after radiotherapy. The trial data focus on patients with lung and breast cancer, especially those at risk of radiation-related lung injury. The studies aim to assess functional and anatomical changes in the lungs.
Key points
- Clinical trials investigating "XENON (133XE)" are focused on lung imaging in patients with lung cancer and breast cancer who are receiving radiotherapy. The main study is a Phase 4 interventional trial with 40 participants. Researchers are looking at pre- and post-treatment ventilation maps to see how radiotherapy changes lung function and lung structure. The main endpoint is to measure these changes both by visual review and by numerical comparison. The trial is also relevant to radiation-induced lung injury, including radiation pneumonitis and radiation fibrosis.
Trial overview
This clinical trial is titled Pre- and post-treatment evaluation of lung function with Xenon-gas enhanced Dual-Energy CT-imaging in patients undergoing radiotherapy.
It is an interventional study, which means researchers actively give the study intervention and then measure what happens.
The trial is testing imaging with a gas mixture of 30 Vol% Xe in 70 Vol% O2 as a contrast agent, used together with Dual-Energy CT imaging to study the lungs.
Who is being studied
The trial includes patients with lung cancer and breast cancer who are scheduled to undergo radiotherapy.
The study also targets people at risk of radiation-induced lung injury, including radiation pneumonitis and radiation fibrosis.
Enrollment is planned for 40 participants, so this is a relatively small study focused on detailed imaging results.
What the trial is measuring
The main endpoint is to quantify radiotherapy-related changes in lung function by comparing pre-treatment and post-treatment ventilation maps.
Researchers will assess these changes in two ways: first by visual review of lung tissue and ventilation patterns, and second by numerical comparison of local ventilation metrics.
The study looks for areas that appear hypo- or hyperdense on colour-coded Xe-concentration maps, because these patterns may show how the lungs respond to treatment.
Phase and status
This trial is listed as Phase 4.
The status is Authorised, which means the study has been approved to proceed.
Phase 4 studies are often used to learn more about how a method performs in a more real-world setting after earlier development stages, although this trial is specifically focused on imaging results rather than treatment effect.
Why this research matters for patients
This research may help doctors and researchers better understand how radiotherapy affects the lungs in people treated for lung cancer or breast cancer.
By comparing lung images before and after treatment, the study may show where lung function changes happen and how strong those changes are.
That information can support future work on monitoring lung injury after radiotherapy, especially for problems such as pneumonitis and fibrosis.